MARKET NEWS


 

Poseida Therapeutics Announces FDA Clearance of IND Application for Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Nuvectis Pharma Raises $15 Million & In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor From the CRT Pioneer Fund
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy & Critical Care Division
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
Quantum Genomics Presents Results From Phase 2b QUORUM Study of Firibastat in Heart Failure
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

  FEATURED EDITORIAL

  COMPANY PROFILE

Experts in subcutaneous drug delivery systems for self-administration, Haselmeier provides innovative and award-winning system solutions to support patients with a successful therapy. Since October 2020, Haselmeier is a business unit of Sulzer AG, Winterthur, Switzerland. Our business covers all steps – from design to planning to industrialization – in the creation of high-quality self-injection systems. Our approach is built on a century of experience – and an open, curious mind. Click here for more.

  EXCLUSIVE ONLINE CONTENT

A Collaborative Effort Paves the Way for a New Approach to Small Batch Manufacturing

A Collaborative Effort Paves the Way for a New Approach to Small Batch Manufacturing

In today’s pharmaceutical industry there is a sharp focus on the needs and requirements of the patient. More and more drugs are being developed for specific patient groups. Orphan drugs, for example,….

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat & Prevent SARS-CoV-2 Infections

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat & Prevent SARS-CoV-2 Infections

Pardes Biosciences, Inc. recently announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral….

Jasper Health & BioIntelliSense Form Strategic Collaboration to Transform Remote Monitoring for Oncology Care

Jasper Health & BioIntelliSense Form Strategic Collaboration to Transform Remote Monitoring for Oncology Care

Jasper Health recently announced it has formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its medical grade….

Fusion Antibodies Partners With Eurofins Discovery to Support Innovative Preclinical Drug Discovery Research

Fusion Antibodies Partners With Eurofins Discovery to Support Innovative Preclinical Drug Discovery Research

Fusion Antibodies plc recently announced it has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE (EUFI.PA) group company; a leading provider of products and services to the….

Adhera Therapeutics Signs Exclusive License Agreement With Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate

Adhera Therapeutics Signs Exclusive License Agreement With Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate

Adhera Therapeutics, Inc. recently announced it has executed an exclusive license agreement with Melior Pharmaceuticals I, Inc. defining the terms and conditions for which Adhera will license MLR-1023….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 15 – Lyophilization Manufacturing
September 22 – Excipients